



April 10, 2025

The Secretary of the Expert Committee on the Selection and Use of Essential Medicines

Medicines Selection, IP and Affordability
Department of Health Products Policy and Standards
20 Avenue Appia
CH-1211 Geneva 27

Dear members of the Expert Committee on the Selection and Use of Essential Medicines, IFPA, formerly known as the International Federation of Psoriasis Association, represents people living with psoriasis and psoriatic arthritis worldwide.

We support the inclusion of ustekinumab (application A.31) in the WHO Essential Medicines List, and the addition of the indication psoriasis for adalimumab (application I.1).

In 2014, the World Health Assembly unanimously adopted resolution WHA67.9 on psoriasis, underscoring that “too many people in the world suffer needlessly from psoriasis due to incorrect or delayed diagnosis, inadequate treatment options and insufficient access to care”.

The inclusion of ustekinumab and the addition of psoriasis as indication for adalimumab, already included in the Essential Medicines List, is a step forward towards ensuring access to adequate treatment for those in need.

In particular, access to ustekinumab would be beneficial in areas with a higher burden of tuberculosis, considering its favorable safety profile, and a steppingstone for health equity.

On behalf of IFPA member organizations and the more than 60 million people living with psoriasis all over the world, we appreciate your attention to this matter, and we hope for a positive decision.

Kind Regards,

Frida Dunger

Executive Director, IFPA



Slottsbacken 8
111 30 Stockholm, SWEDEN



ifpa-pso.com
info@ifpa-pso.com



@psoriasisIFPA